2874-72-8

Basic information

• Product Name: 2-DECYLDODECANOIC ACID
• Synonyms: 2-DECYLDODECANOIC ACID;Dodecanoic acid,2-decyl-
• CAS NO: 2874-72-8
• Molecular Formula: C₂₂H₄₄O₂
• Molecular Weight: 340.58
• Mol File: 2874-72-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-DECYLDODECANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-DECYLDODECANOIC ACID(2874-72-8)
• EPA Substance Registry System: 2-DECYLDODECANOIC ACID(2874-72-8)

Safety Data

• Hazardous Substances Data: 2874-72-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Decyldodecanoic Acid is used as a reactant for the synthesis of Vizantin, a compound developed as a safe immunostimulant. It plays a crucial role in enhancing the immune response and has potential applications in the treatment of various diseases and conditions.
Used in Chemical Synthesis:
2-Decyldodecanoic Acid can be utilized as a building block in the synthesis of various complex organic compounds, such as surfactants, lubricants, and additives. Its unique structure and properties make it a valuable component in the development of new materials with specific characteristics and functions.

Upstream product

• 5860-64-0 bis-decyl-malonic acid 
• 112-29-8 1-bromo dodecane 
• 112008-98-7 diethyl 2,2-didecylmalonate 
• 2050-77-3 Iododecane 
• 105-53-3 diethyl malonate 
• 143-07-7 lauric acid 

Downstream Products

• 180476-40-8 (2S,4S,5R,6R)-4-Acetoxy-5-acetylamino-2-[(2R,3S,4S,5R,6R)-3,5-bis-benzoyloxy-2-benzoyloxymethyl-6-(2-decyl-dodecyloxy)-tetrahydro-pyran-4-yloxy]-6-((1S,2R)-1,2,3-triacetoxy-propyl)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 815581-19-2 2-decyl-1-phenyl-dodecan-1-one 
• 858487-62-4 2-decyl-1-(4-decyl-phenyl)-dodecan-1-one 
• 6704-00-3 heneicosane 
• 1223421-04-2 6,6'-bis-O-(2-decyldodecanoyl)-2,3,4,2',3',4'-hexabenzyl-α,α'-trehalose 

Relevant articles and documents

Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6′-dicorynomycolate

Vizantin, 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′- trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6′- dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.

TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND

It is an object of the present invention to provide a trehalose compound having high immunopotentiating activity and low toxicity. The trehalose compound is represented by formula (1). (In the formula, X and X' each represents a phenyl, a naphtyl, R1-CHR1- (wherein R1 and R2 each represents a C7-C21 alkyl group or the like) or the like; and n and n' each independently represents an integer of 0-3). The compound exhibits a high activating effect on macrophages and neutrophils.

TREHALOSE COMPOUND, PROCESS FOR PRODUCTION OF THE COMPOUND, AND IMMUNO-STIMULATIVE AGENT COMPRISING THE COMPOUND

An object of the present invention is to provide a novel trehalose compound that exhibits excellent immunostimulating activity and that can be supplied in a large quantity in an industrial scale, and a method for producing the trehalose compound, wherein

Use of branched chain fatty acids and derivatives thereof for inhibition of P-glycoprotein

The invention relates to the use of branched chain fatty acids (BFAs) and their derivatives for inhibition of the activity of P-glycoprotein (P-gp). In particular, the invention relates to the use of BFAs and their derivatives in the treatment of multi-drug resistant (MDR) tumors associated with increased activity of P-glycoprotein. The invention also relates to the use of the above-mentioned molecules for administration of biologically active molecules and diagnostic agents into cells associated with increased activity of P-gp, and for increasing accumulation of biologically active molecules and diagnostic agents in organs protected by biological barriers.